Johnson & Johnson reports 2-year psoriasis data for Icotyde

Johnson & Johnson announced long-term data on October 2, 2026, from the Phase 3 ICONIC-TOTAL study of Icotyde (icotrokinra). The once-daily oral peptide demonstrated sustained skin clearance over two years in adults and adolescents aged 12 and older with moderate-to-severe plaque psoriasis in difficult-to-treat areas.

The findings, presented at the European Academy of Dermatology and Venereology Congress 2026, showed that the rate of clear or almost clear skin rose from 57% at week 16 to 67% at week 24 and reached 70% at week 112.

At week 112, 60% of patients with scalp psoriasis, 89% with genital psoriasis, and 63% with psoriasis on the hands or feet achieved complete site-specific clearance. Mean improvement on the modified Nail Psoriasis Severity Index reached 71%, up from 33% at week 16 and 62% at week 52. Safety findings through week 112 remained consistent with earlier data, showing no new safety signals.

Icotyde, which blocks the IL-23 receptor, was jointly discovered with Protagonist. Johnson & Johnson holds exclusive worldwide commercialization and late-stage clinical development rights. The medicine is approved in the United States, Europe, Japan, and China for moderate-to-severe plaque psoriasis, and is also undergoing clinical trials for psoriatic arthritis, ulcerative colitis, and Crohn's disease.